Monitoring of Pregnancy-Induced Hypertension Syndrome Combined with Ultrasound Monitoring in Early Pregnancy to Prevent Chronic Hypertension with Preeclampsia

Background: This study explored the guiding value of monitoring pregnancy-induced hypertension syndrome (MP) for blood hyperco-agulability in combination with ultrasound monitoring of uterine artery blood flow in early pregnancy and fetal growth and development in the second and third trimesters, with the goal of preventing chronic hypertension with preeclampsia (PE) and its clinical effects. Meth-ods: The medical records of 189 pregnant patients with chronic hypertension between June 2016 and June 2021 were retrospectively analyzed; among them, 98 constituted the intervention group. The intervention group received MP screening for blood hypercoagulability in combination with ultrasound monitoring of uterine artery blood flow in early pregnancy and fetal growth and development in the sec-ond and third trimesters of pregnancy. Those with abnormalities were given timely symptomatic (low-molecular-weight heparin with or without aspirin) and supportive treatment. The remaining 91 patients who did not receive timely monitoring and intervention constituted the control group. Fetal outcomes and PE rates were compared between groups. Results: The PE incidence in the intervention group was significantly lower than that in the control group (p < 0.01), and the premature delivery of low-birth-weight neonates, fetal loss and neonatal asphyxia incidences were also significantly lower in the intervention group than the control group (p < 0.05). Conclusions: MP screening for blood hypercoagulability combined with ultrasound monitoring of uterine artery blood flow can effectively prevent PE occurrence in pregnant patients with chronic hypertension and significantly improve fetal outcomes. Additionally, MP screening is noninvasive and easy to use at a low cost.